Sirolimus: A new agent for prevention of renal allograft rejection

American Journal of Health-System Pharmacy

Volumn 57, Issue 5, 2000, Pages 437-451

  Vasquez, Eva M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Dosage; Drug interactions; Graft rejection; Immunosuppressive agents; Mechanism of action; Pharmacokinetics; Sirolimus; Toxicity; Transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ANIMAL; CLINICAL TRIAL; COMPARATIVE STUDY; GRAFT REJECTION; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; REVIEW;

ANIMALS; CLINICAL TRIALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS;

EID: 0034145650     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.5.437     Document Type: Article

References (37)

1. Seghal SN, Baker H, Vezina C. Rapamycin (AY-22,989) a new antifungal antibiotic II. Fermentation, isolation and characterization. JAntibiot. 1975; 28:727-31.
2. Calne RY, Lim S, Samaan A et al. Rapamycin for immunosuppression in organ allografting. Lancet. 1989; ]uly:227.
3. Chen H, Wu ], Xu D et al. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Transplantation. 1993; 56:661-6.
4. Rapamune (sirolimus) solution package insert. Philadelphia: Wyeth-Ayerst Pharmaceuticals, Inc. 1999.
5. Terada N, Lucas JJ, Szepesi A et al. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G, phase of the cycle. / Cell Physiol. 1993; 154:7-15.
6. Aagaard-Tillery KM, Jelinek DF. Inhibition of B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol. 1994; 156:493-507.
7. Taylor-Fishwick DA, Kahan M, Hiestand P et al. Evidence that rapamycin has differential effects on IL-4 function. Transplantation. 1993; 56:368-74.
8. Kimball PM, Kerman RH, Kahan BD. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation. 1991;51:486-90.
9. Vathsala A, Ting-Chao C, Kahan BD. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. Transplantation. 1990; 49:463-72.
10. Seghal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit. 1995; 17:660-5.
11. Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol. 1998; 10:3306.
12. Hatfield SM, Mynderse JS, Roehm NW. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists. / Pharmacol Exp Ther. 1992; 261:970-6.
13. Chen H, Qi S, Xu D et al. FK506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. Transplant Proc. 1998; 30:1039-41.
14. Cao W, Mohacsi P, Shorthouse R et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Transplantation. 1995; 59:390-5.
15. YatscoffRW. Pharmacokinetics of rapamycin. Transplant Proc. 1996; 28:970-3.
16. Gregor CR, Huang X, Pratt RE et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimai thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995; 59:655-61.
17. Gregory C, Huie P, Billingham ME et al. Rapamycin inhibits arterial intimai thickening caused by both alloimmune and mechanical injury. Transplantation. 1993; 55: 1409-18.
18. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. / Clin Pharmacol. 1997; 37:405-15.
19. Brattström C, Säwe ], Tydén G et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit. 1997; 19:397-406.
20. Yatscoff R, LeGatt D, Keenan R et al. Blood distribution of rapamycin. Transplantation. 1993; 56:1202-6.
21. Perron GM, Mishina EV, Zimmerman JJ et al. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther. 1997; 61:416-28.
22. Slatter M, Guengerich FP, Yun CH et al. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rats. Drug Metab Dispos. 1992; 20:753-61.
23. Christians U, Sattler M, Schiebe! HM et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos. 1992; 20:18691.
24. Yatscoff RW, Wang P, Chan K et al. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit. 1995; 17:666-71.
25. Kahan BD. Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients. Transplant Proc. 1998; 30:2185-8.
26. Kahan BD. A Phase III comparative efficacy trial of Rapamune in renal allograft recipients. Presented at the 27th World Congress of the Transplantation Society. Montreal, Canada. Jul 14 1998.
27. The Rapamune Global Study Group. A randomized placebo-controlled trial of Rapamune in primary renal allograft recipients. Presented at the 27th World Congress of the Transplantation Society, Montreal, Canada. Jul 16 1998.
28. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation. 1999; 67:1036-42.
29. Neylan JF, Pescovitz MD, Julian BA et al. Multi-center Phase II trial of sirolimus in renal transplantation: immunosuppressive requirements for black patients. Presented at the 16th International Congress of the Transplantation Society, Barcelona, Spain. Äug 25-30 1996.
30. Kahan BD, Podbielski J, Van Buren CT. Rapamycin for refractory renal allograft rejection. Transplantation. 1998; 66:5180. Abstract.
31. Kahan BD, Pescovitz M, Chan G et al. Oneyear outcome after steroid withdrawal from a sirolimus-cyclosporine-prednisone regimen in cadaver- and living-donor recipients. Transplantation. 1998; 66:5167. .
32. Brattstrom C, Wilczek HE, Tyden G et al. Hypertriglyceridemia in renal transplant re-cipients treated with sirolimus. Transplant Proc. 1998; 30:3950-1. i
33. Kaplan B, Meier-Kriesché HU, Napoli KL et al. The effects of relative timing of sirolimus and cydosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther. 1998; 63:48-53.
34. Cardinale V, ed. 1999 Drug topics red book. Montvale, NJ: Medical Economics; 1999.
35. Sedrani R, Cotton S, Kallen J et al. Chemical modification of rapamycin: the discovery of SDZRAD. Transplant Proc. 1998; 30:2192-4.
36. Crowe A, Bruelisauer A, Duerr L et al. Absorption and intestinal metabolism of SDZ RAD and rapamycin in rats. Presented at the 16th International Congress of the Transplantation Society, Barcelona, Spain. Aug 25-30 1996.
37. Kahan B, Wilkie M, Appel Dingemanse S et al. Safety and tolerability of the immunosuppressant SDZ RAD in stable renal transplant recipients. Transplantation. 1998; 65:576. .